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ABSTRACT
Background Tumor microenvironment- associated T cell 
senescence is a key limiting factor for durable effective 
cancer immunotherapy. A few studies have demonstrated 
the critical role of the tumor suppressor TP53- derived 
p53 isoforms in cellular senescence process of non- 
immune cells. However, their role in lymphocytes, in 
particular tumor- antigen (TA) specific T cells remain largely 
unexplored.
Methods Human T cells from peripheral blood were 
retrovirally engineered to coexpress a TA- specific T cell 
receptor and the Δ133p53α-isoform, and characterized 
for their cellular phenotype, metabolic profile and effector 
functions.
Results Phenotypic analysis of Δ133p53α-modified 
T cells revealed a marked reduction of the T- cell 
inhibitory molecules (ie, CD160 and TIGIT), a lower 
frequency of senescent- like CD57+ and CD160+ 
CD8+ T cell populations, and an increased number 
of less differentiated CD28+ T cells. Consistently, we 
demonstrated changes in the cellular metabolic program 
toward a quiescent T cell state. On a functional level, 
Δ133p53α-expressing T cells acquired a long- term 
proliferative capacity, showed superior cytokine secretion 
and enhanced tumor- specific killing in vitro and in mouse 
tumor model. Finally, we demonstrated the capacity of 
Δ133p53α to restore the antitumor response of senescent 
T cells isolated from multiple myeloma patients.
Conclusion This study uncovered a broad effect of 
Δ133p53α isoform in regulating T lymphocyte function. 
Enhancing fitness and effector functions of senescent T 
cells by modulation of p53 isoforms could be exploited 
for future translational research to improve cancer 
immunotherapy and immunosenescence- related diseases.
BACKGROUND
Adoptive cellular therapy using T cells engi-
neered to recognize tumor- associated anti-
gens or neoantigens following viral transfer 
and expression of T cell- receptor (TCR) 
encoding genes has advanced as a promising 
and personalized immunotherapy for chemo-
refractory leukemia and solid cancer.1 2 
Encouraging results have been achieved in 
clinical trials using TCR transduced T cells. 
However, further improvements are needed 
to achieve durable responses.3 Potential obsta-
cles of therapeutic efficacy are likely associ-
ated with ineffective trafficking and homing 
of T cells to and within the tumor.2 Moreover, 
multiple immunosuppressive mechanisms 
mediated by, for example, the interaction of 
programmed cell death ligand 1 (PD- L1) or 
poliovirus receptor (PVR, CD155) expressed 
on tumor cells with programmed cell death 
1 (PD-1) and T cell immunoreceptor with 
Ig and ITIM domains (TIGIT) upregulated 
on T cells can counteract T cell effector 
functions.4–6 The development of antibodies 
blocking these negative regulators (immune 
checkpoints) represents a breakthrough in 
cancer immunotherapy and has led to durable 
responses in various cancer types.7 8 Ulti-
mately, the tumor microenvironment (TME) 
drives T cells to an exhausted or senescent 
state with terminal differentiation character-
ized by poor proliferation and impaired anti-
tumor responses.9 Engineering T cells that 
are less prone to tumor- driven dysfunction is 
therefore fundamental to improve antitumor 
responses in patients.
Cellular senescence displays a state of 
permanent proliferation arrest and is classi-
fied as either telomere- dependent (replicative 
senescence) due to a limitation of prolifer-
ative capacity10 or telomere- independent 
(premature senescence) due to external 
stimuli, such as oncogenic stress.11 Increasing 
numbers of senescent T cells are associated 
with many pathological conditions, such as 
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infection and cancer.12 13 Moreover, senescent T cells accu-
mulate during the normal lifespan of healthy individuals 
as well. These cells are mainly characterized by downregu-
lation of the costimulatory molecule CD28 and increased 
expression of CD57,13 CD160, KLRG1, and exhibit an 
extenuated response to antigen stimulation.14 15 Although 
the mechanisms which regulate T cell senescence remain 
unclear, the tumor suppressor p53 emerged as a potential 
key player. TP53 has a crucial role in the maintenance of 
the genetic stability and, thus the prevention of cancer 
formation. It induces a number of cellular responses 
including DNA repair, cell cycle arrest and apoptosis. TP53 
regulates the expression of many genes and is involved in 
cellular senescence.16 17 The finding that the human p53 
gene contains an alternative promotor and transcribes 
multiple splice variants, resulting in the expression of 12 
different protein isoforms p53 (α, β, γ), Δ40p53 (α, β, γ), 
Δ133p53 (α, β, γ), and Δ160p53 (α, β, γ)18 19 highlight 
the complexity of the p53 network. The human isoforms 
that are most associated with cellular senescence are 
the C- terminally and the N- terminally truncated p53β 
and Δ133p53α. The p53β protein isoform contains the 
transactivation domains (TAD) and the DNA- binding 
domain (DBD) but terminates with 10 additional amino 
acids, lacking half of the classic oligomerization domain, 
a nuclear export signal (NES) domain and the negative 
regulation domain. In contrast, Δ133p53α lacks both of 
the TAD and part of the second conserved region of the 
DBD but contains the NES. These two naturally occurring 
p53 isoforms act as physiological regulators of cellular 
proliferation and senescence in normal human fibro-
blasts, in human T lymphocytes,13 20 but also in human 
brain astrocytes and in induced pluripotent stem cells.21 22 
In mice, the first report revealing that the p53 gene codes 
for more than one functional protein was published by 
Rotter and colleagues back in 1985,23 describing the pres-
ence of another p53 variant in transformed fibroblasts as 
a result of alternative splicing of intron 10, named p53AS 
(alternatively spliced). Later, MΔ41p53, the mouse coun-
terpart of human Δ40p53α forms was isolated.24 In addi-
tion, a shorter N- terminal form produced by an internal 
promoter within the mouse p53 gene, MΔ157p53, 
equivalent to the human Δ160p53 form was identified. 
It was also shown that MΔ41p53 and MΔ157p53 can 
be expressed as a C- terminal AS variant.25 However, in 
contrast to human and high order primates, mice do 
not produce Δ133p53 isoforms or beta isoforms. Trans-
genic mice overexpressing Δ40p53 present an increased 
cellular senescence, a slower growth rate, and premature 
aging phenotype due to abnormal hyper- activation of the 
insulin- like growth factor signaling.26 Mechanistically, 
while human p53β can bind differentially to promoters 
and enhance expression of senescence- associated p53 
target genes, Δ133p53α modulates gene expression 
and increases DNA- repair efficiency through interac-
tion with full- length p53 and homologous p53 protein, 
p63 and p73.27–29 Δ133p53α also directly binds DNA on 
a novel type of p53- responsive element in enhancer and 
promoters to regulate gene transcription.29Δ133p53α 
also acts as a dominant negative inhibitor of senescence 
genes.18 30 Overexpression of Δ133p53α in near senes-
cent human fibroblasts extends the cellular replicative 
lifespan by inhibiting the expression of p21Waf1/Cip1 and 
other p53 transcriptional target genes, including microR-
NA- 34a. In contrast, overexpression of p53β induces 
cellular senescence by the upregulation of p53 target 
genes such as p21Waf1/Cip1 via cooperation with full- length 
p53.13 Although in T lymphocytes, the role of these two 
p53 isoforms as potential regulators of cellular senescence 
has been reported,20 their function in more complex and 
tissue- specific context, including immune- related disor-
ders or cancer remains unexplored.
Here, we demonstrated for the first time that gene 
expression of the Δ133p53α isoform in tumor- antigen 
(TA) TCR- engineered T cells improves effector functions 
in vitro assays and in a mouse model of adoptive T cell 
transfer. Circumventing senescence in antigen receptor- 
redirected T cells by genetic modification with Δ133p53α 
provides a novel strategy to improve robustness and resil-
ience of antitumor responses.
METHODS
Animal studies
CyA2Kb,31 OT- I and NOD.Cg- PrkdcscidIL2rgtm1Wjl/SzJ 
(NSG) mice were obtained from the central animal 
facility of the Johannes Gutenberg University Mainz, 
Germany. CyA2Kb and OT- I mice were used as source of 
donor splenocytes and NSG mice as recipient animals for 
tumor models. NSG mice were injected (s.c.) with osteo-
sarcoma cell line Saos2/143 in the left flank and adop-
tively transferred (intravenous) with genetically modified 
human CD3+ T cells as previously published.31 Mice were 
sacrificed when the tumor size was 1 cm3 (or at termina-
tion of the study), and freshly isolated tumors and spleens 
were dissociated by mincing the tissue with scalpels into 
0.5 mm small pieces. Dissociated tissue was further tritu-
rated and filtered through a 100 µm cell strainer to obtain 
single- cell suspension and analyzed by flow cytometry. 
Serum was obtained from the peripheral blood at the 
time of sacrifice.
Blood samples, primary cells and cell lines
Buffy Coats from healthy donors were obtained from 
the Transfusion Center of the University Medical Center 
Mainz and the Institute for Immunology/IKTZ, Heidel-
berg University, Germany. Primary human T cells were 
obtained from the peripheral blood of patients with newly 
diagnosed multiple myeloma (MM). Peripheral blood 
mononuclear cells were isolated from peripheral blood 
via ficoll density gradient centrifugation. Tumor cell lines 
used in this study included the human HLA- A2.1+ p53 
null osteosarcoma Saos2, its p53- transfectant Saos2/14331 
and the C57BL/6- derived colon carcinoma MC38- OVA 
and melanoma B16- OVA. The A2Kb p53mutant MEF 
tumor cell line was described earlier.31 Human cell lines 
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were maintained in RPMI 1640 supplemented with 10% 
heat inactivated fetal calf serum (FCS), 2 mM L- gluta-
mine, 100 U/mL penicillin and 0.1 mg/mL streptomycin. 
Murine tumor cell lines were maintained in DMEM 
(GIBCO) supplemented with 10% FCS, 25 mM HEPES- 
buffer, 1% glutamine, and 1% penicillin- streptomycin.
Peptides, antibodies and reagents
HLA- A2.1 restricted p53aa264-272 (LLGRNSFEV) was synthe-
sized by Biosyntan (Berlin, Germany) and dissolved 
in DMSO. Antibodies used for Western blotting were 
mouse monoclonal antibodies (mAb) antihuman p53 
(DO-2) sc-53394 (Santa Cruz Biotechnology, Heidelberg, 
Germany), antihuman p53 (HR231) MA1-12648 (Invit-
rogen), sheep antihuman p53 isoforms KJC12 (gift from 
Bourdon, Dundee, UK), rabbit mAbs anti- tri- methyl- 
Histone H3 (Lys4) (C42D8), anti- tri- methyl- Histone 
H3 (Lys9) (D4W1U) (Cell Signaling Technology), anti- 
HIF1a (Ab92498) (Abcam), rabbit mAb anti- Akt (pan) 
(C67E7) (Cell Signaling Technology, Cambridge), rabbit 
mAb anti- p21 (ab109520) (Abcam) and the mouse mAb 
anti- MDM2 (SMP14) sc-965 (Santa Cruz). Bafilomycin A1 
(InvivoGen) was used as autophagy blocker.
Genetic Modification of T Lymphocytes
cDNA encoding for human Δ133p53α and p53β (gift 
from Bourdon, Dundee, UK) were cloned into the 
retroviral vector pMx_Ires_puromycin (RTV-014, Cell 
Biolabs) via BamHI/NotI. As a TA model, we used our 
high- affinity sc p53TCR specific for the broadly expressed 
(non- mutant) HLA.A2.1- restricted p53aa264-272 peptide. 
The original scTCR scaffold was described earlier,26 
and the cDNA- encoding sequence was further codon- 
modified (Invitrogen GeneArt, Regensburg, Germany) 
and cloned into one single bicistronic 2A- based retroviral 
vector.24 We used the pGMP retroviral vector encoding 
the scTCR31 for gene transfer in murine T cells. To redi-
rect human T cells, the scTCR coding sequence was 
cloned into the retroviral vector pBullet_Ires_neomycin32 
via NcoI/BamHI. Retroviral transduction, selection and 
expansion of human and mouse bulk CD8+/CD4+ T cells 
(with CD3/CD28- beads or by peptide- specific stimulation 
(K562_A2+_CD80+ pulsed with 10 µg p53 peptide) were 
performed as described earlier.31 33 Separation of human 
CD8+ T cell fractions (TIGIThigh and TIGITlow) was 
performed with MACS cell separation beads (Miltenyi 
Biotec) according to the manufacturer’s protocol.
Flow cytometry analysis
Antibodies used in this study are listed in online supple-
mental table S1. Cells were stained according to the 
manufacturer’s instructions. To detect the expression of 
the lysosomal- associated membrane protein 1 (LAMP1/
CD107a) (as a surrogate marker for degranulation) on 
the surface of CD8+ T- cells, effector cells were incubated 
for 24 hours with target tumor cells in the presence of 
monensin (Monensin Solution 1000X, eBioscience) and 
the CD107a antibody. Phorbol 12- myristate 13- acetate 
(PMA) + ionomycin (Sigma- Aldrich) were used as control 
inducers of CD107a expression. The determination of 
apoptotic cells was performed with a standard Annexin 
V and propidium iodide (PI) (BD Biosciences) staining 
according to the manufacturer’s instructions. TCR Vβ 
repertoire of TCR- engineered T cells in vivo was analyzed 
by flow cytometry with antibodies from the Beta Mark 
TCR Vβ Repertoire Kit (Beckman Coulter) directed 
against 19 individual TCR/Vβ chains. Flow cytometry 
acquisitions were performed on a FACSCanto II and BD 
FACSLyric (BD Biosciences), and data were analyzed with 
FlowJo_V10 software (Tree Star).
T cell functional assays
T cell proliferation in vitro was assessed by carboxyfluores-
cein succinimidyl ester (CFSE) dilution assay. T cells were 
labeled with 5 µM CFSE for 5 min and subsequently stim-
ulated with antigen- presenting cells as described before. 
Cells were analyzed at the indicated time points for CFSE 
dilution by flow cytometry. Standard 5h 51Cr- release assays 
were performed at the indicated effector- to- target (E:T) 
ratio in duplicate wells as described earlier.31 Long- term 
killing capacity of TCR- engineered T cells was deter-
mined by colony forming assay (CFA). Briefly, effector 
T cells were cocultured with antigen+ (Saos2/143) or 
antigen- (Saos2) target tumor cells in 6- or 12- well plates 
at 37°C with 5% CO2 at the indicated E:T ratio. After 
24 hours, T cells as well as non- adherent lysed tumor cells 
were washed out and if necessary, transferred to a second 
round of fresh tumor cells. The remaining adherent 
viable tumor cells were fixed with 4% PFA for 10 min at 
room temperature (RT) and subsequently stained with 
1% crystal violet dye (Merck KGaA, Germany) for 15 min 
at RT. Crystal violet was washed off by adding Phosphate 
buffered saline (PBS) and the plate scanned for visual eval-
uation of colony counts. For quantitative analysis, the dye 
was dissolved by adding 5% SDS and the corresponding 
optical density (absorbance) measured at 570 nm using a 
microplate reader (Dynex MRX, Magellan BioScience). 
Replicative senescence of T cells in vitro was evaluated by 
calculating the population doubling levels (PDLs) using 
the following formula as described in20 : log10(number of 
cells after expansion) - log10(number of cells seeded)/
log102. Secreted cytokines/chemokines in vitro culture 
and in serum were determined by Luminex Multiplex 
Assays (MAGPIX) using Human Cytokine & Chemokine 
(34 plex) kit (eBioscience, San Diego, USA) according 
to the manufacturer protocol. For in vitro assays, effector 
T cells and target cells were cocultured in 12- well plates 
before for 24–48 hours as described for CFA and cytokine 
concentrations measured in the culture supernatant. 
Serum was diluted 1:5 before measurement.
T cell metabolic assays
The oxygen consumption rate (OCR) and the extracel-
lular acidification rate (ECAR) were measured using the 
Seahorse XFp Analyzer (Agilent). Culture Miniplates 
were coated, using Poly- D- Lysine (Sigma P6407). To each 
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well, 50 µL of Poly- D- Lysine was added. After an incu-
bation time of 1 hour at RT, the wells were rinsed with 
sterile water. XFp Sensor Cartridge wells were hydrated 
by adding 200 µl XF calibrant to each well and 400 µL 
to each outside well. Cartridges were then stored in a 
non- CO2 incubator at 37°C overnight. XFp Cell Energy 
Phenotype Test Kit (Agilent) was performed according 
to the manufacturers’ protocol. In detail, 1.0×106 T cells 
per well were seeded in XF Base Medium (DMEM). The 
medium was supplemented with 10 mM glucose, 1 mM 
sodium pyruvate and 2 mM L- Glutamine and the pH was 
adjusted to 7.4. Using the Cell Energy Phenotype Test Kit, 
OCR and ECAR were measured under basal steady- state 
conditions (unstimulated T cells) and under stressed 
conditions. The stressed condition was induced by injec-
tion of 1 µM (final concentration) oligomycin and 1 µM 
(final concentration) fluoro- carbonyl cyanide phenyl-
hydrazone (FCCP). The results were analyzed using the 
Seahorse Wave Desktop Software.
Western blotting
Proteins were extracted from T cells using lysis buffer 
(Pepstatin, PMSF 100 mM, Sodium fluoride 1M, Sodium 
orthovanadate, Leup, 1% Brij 96 V solution) (Sigma- 
Aldrich). Protein concentration was determined by a DC 
Protein Assay (BioRad) according to the manufactur-
er’s recommendations. Western blotting was performed 
according to Bourdon’s (Dundee, UK) guidelines using 
reagents and devices from ThermoFisher Scientific. In 
brief, samples were loaded on a precast polyacrylamide 
gel (Bolt 10% Bis Tris Plus) and separated by electro-
phoresis. Samples were transferred to a nitrocellulose 
membrane (iBlot 2 Transfer Stacks) using the iBlot 2 
Dry Blotting System. Membranes were blotted with the 
primary antibodies (listed above) overnight at 4°C and 
detected with anti- rabbit HRP- conjugated secondary anti-
body 7074S (Cell Signaling Technology, Cambridge, UK) 
(dilution 1:5000), anti- mouse HRP- conjugated secondary 
antibody sc-2005 (Santa Cruz Biotechnology, Heidelberg, 
Germany) (dilution 1:2000) anti- sheep HRP- conjugated 
secondary antibody ab7111 (Abcam, Cambridge, UK) 
(dilution 1:5000) for 1 hour at RT. Finally, chemilumi-
nescence was detected with iBright Western Blot Imaging 
System after 5 min incubation with SuperSignal West 
Femto substrate (ThermoFisher Scientific) and 1 min 
exposure time.
Quantitative real-time PCR
Total RNA was extracted from T cells with the RNeasy Mini 
Kit (Qiagen) according to the manufacturer’s protocol. 
RNA concentration was determined using the NanoDrop 
One (ThermoFischer Scientific). To generate cDNA, 
reverse transcription was performed with 2 µg of RNA 
and the High- Capacity cDNA Reverse Transcription Kit 
(ThermoFischer Scientific). Primers are listed in online 
supplemental table S2. The GeneTouch Thermal Cycler 
(Biozym Scientific) was used for reverse transcription 
with the following thermal conditions: 10 min at 25°C, 
60 min at 37°C and 5 min at 85°C. Relative expression of 
transcripts was determined by quantitative real- time- PCR 
using the PowerUp SYBR Green master mix (Applied 
Biosystems) and QuantStudio 3 system (Applied Biosys-
tems). The ΔΔCt method was used according to the manu-
facturer’s protocol (Real- time PCR handbook, Applied 
Biosystems) to determine fold difference in expression 
normalized to the reference gene as indicated.
Statistical analysis
Statistical analysis of differences between groups was 
determined by two- tailed Student’s t test or log- rank test 
for mouse studies using GraphPad Prism V.5.01.(*P<0.05, 
**p<0.01,***p<0.005).
RESULTS
Δ133p53α modulates the phenotype of CD8+ T cells toward a 
less senescent state
T cells isolated from healthy donors, were retrovirally 
transduced with the p53 isoform Δ133p53α or empty 
vector (mock control) and characterized for prolifer-
ation, phenotype and major effector functions. Gene- 
modified T cells were selected by puromycin treatment. 
The overexpression of Δ133p53α was confirmed by 
western blot (figure 1A). The blot showing p53β expres-
sion was used as a control to validate the specificity of 
the antibodies directed against either the N- terminal or 
C- terminal domain of p53. Functional validation of the 
Δ133p53α isoform was confirmed by the downregulation 
of the p53 senescence- associated gene p21Waf1/Cip1 and the 
MDM2- master regulator of p53, as reported previously13 
(online supplemental figure S1). Additionally, the cells 
were equipped with an antigen- specific TCR (scTCR),31 33 
allowing us to study the effect of Δ133p53α on antigen- 
specific T cells. T cells coexpressing the p53 isoform 
and the scTCR were selected by puromycin + neomycin 
treatment. TCR expression as determined by cell surface 
staining with an anti- TCRVβ3 specific antibody was similar 
between Δ133p53α-overexpressing (57.6%) and control 
(51.5%) CD8+ T cells (figure 1B). Also, the frequency 
of CD8+ and CD4+ T cell subsets remained unchanged 
(figure 1C). CD8+ T cells were further characterized for 
the expression of differentiation markers by flow cytom-
etry analysis. T cell populations with distinct phenotypes 
and functional properties can be identified by the expres-
sion/loss of CD28 and CD57 markers. During aging, 
the number of senescent- like CD28-CD57+CD8+ T cells 
increases, while the frequency of early- activated (non- 
differentiated) CD28+CD57-CD8+ T cells decreases. The 
frequencies of the CD28+CD57- (referred to as CD28 
single positive, SP) population and CD62L- expressing 
cells were significantly higher in Δ133p53α-T cells 
compared with control cells shortly after transduction. In 
addition, expression of the costimulatory molecule CD27 
and the chemokine receptor CCR7, which are lost in 
differentiated T cells (ie, in effector memory or terminal 
effector phenotype) were increased in Δ133p53α-T cells. 
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However, the percent of CD28-CD57+ (CD57SP) T cells 
remained comparable in both groups (figure 1D). Senes-
cent or dysfunctional- T cells are also characterized by 
the expression of specific immune checkpoints. After 
several weeks of in vitro culture, the expression of inhib-
itory receptors was assessed. Among tumor- associated 
Figure 1 Δ133p53α modulates expression of exhaustion markers and inhibitory receptors on T cells. (A) Immunoblot 
confirming the overexpression of p53β and Δ133p53α isoforms after retroviral transduction and puromycin selection of human T 
cells. Empty vector was used for control cells. (B) Representative data for the cell surface expression of the transduced scTCR 
in CD8+ T cells, which was determined by flow cytometry using anti- TCRVβ3 mAb. (C) Percentage of CD8+ and CD4+ T cells for 
paired samples of Δ133p53α-modified or control T cells from healthy donors (n=12 biological replicates). (D) Flow cytometry 
data for cell surface expression of CD28, CD57, CD62L, CD27 and CCR7 for paired samples of Δ133p53α-modified or control 
T cells from different donors, shortly after transduction (n=5–16). Analysis of the cellular phenotype of T cells was carried out 
at early stage (1–3 weeks) after transduction. (E) Difference in PD-1 (p=0.1848), TIGIT and CD160 expression between control 
and Δ133p53α-transduced cells demonstrated in box plots. Error bars indicate SE of mean (SEM). SP stands for single positive. 
*P<0.05, **p<0.01, ***p<0.001, ns (not significant), by two- tailed Student’s t- test. scTCR, single- chain T cell- receptor.
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senescence factors and terminally differentiated markers, 
CD160 and TIGIT were expressed on a lower frequency 
in Δ133p53α-modified T cells (figure 1E), suggesting 
a less senescence phenotype. Of note, although the 
frequency of PD-1+CD8+ T cells was lower on expression 
of Δ133p53α, it did not reach significance (p=0.1848).
Δ133p53α triggers metabolic reprogramming in T cells
Beside the cellular phenotype and differentiation status, 
T cell function relies on the uptake of nutrients and 
adequate energy production. Therefore, the metabolic 
program is adapted to meet the metabolic demands 
and functional needs.34 Resting cells, like naïve T cells, 
remain in a cellular and metabolic quiescent state.34 35 
On antigen- recognition and activation, however, T cells 
increase aerobic glycolysis and mitochondrial oxidative 
phosphorylation (OXPHOS) activity for clonal expan-
sion.36 37 To further characterize Δ133p53α-transduced 
T cells, we assessed their dynamic metabolic reprogram-
ming by XFp Extracellular Flux analysis early after trans-
duction. Under basal conditions, as well as after OXPHOS 
inhibition and mitochondrial uncoupling (=stressed 
conditions), Δ133p53α-T cells had a decreased glycolytic 
activity, measured by the ECAR and a reduced (OCR, 
indicator of OXPHOS) (figure 2A). Corresponding to 
the less differentiated cellular phenotype, the reduced 
activity of glycolysis and OXPHOS indicates a quiescent 
metabolic phenotype of Δ133p53α-T cells under basal 
conditions compared with control cells (figure 2B). 
These data provide evidence that Δ133p53α-overexpres-
sion does not only lead to changes in cellular phenotype, 
but is also associated with bioenergetic shifts toward a 
more quiescent metabolic phenotype (figure 2C), with 
the capacity to adapt their metabolic activity to the func-
tional needs. To further, document these metabolic 
differences, we included the analysis of the glucose trans-
porter 1 (GLUT1), which is also differently express in 
quiescent/naïve vs effector T cells.38 Concordantly, we 
observe a lower expression intensity in Δ133p53α-T cells 
as compared with controls (figure 2D), which correlate 
with their ‘quiescent- like’ phenotype. However, expres-
sion analysis of HIF- 1a, as an additional factor in the meta-
bolic transition to glycolysis, did not show a significant 
change (figure 2E). These results suggest the metabolic 
switch in Δ133p53α-T cells is most likely HIF- 1a indepen-
dent process.
Overexpression of Δ133p53α invigorates T cell proliferation 
and improves effector functions of TCR-engineered T cells
In order to estimate the long- term proliferative capacity of 
Δ133p53α-T cells, we determined the PDL of aging cells 
in culture. Although cumulative PDL values were similar 
in the logarithmic phase, the proliferation index (or life- 
span) of control T cells reached a plateau around week 14, 
indicating a cellular senescence state, while Δ133p53α-T 
cells remained strongly proliferative (figure 3A). To 
confirm this finding, we compared the proliferation ability 
Δ133p53α-modified and control T cells at late timepoints 
of in vitro culture in a CFSE- based proliferation assay and 
noticed a higher cell division rate in Δ133p53α-T cells as 
demonstrated by lower mean fluorescence intensity (MFI) 
values of CFSE dye (figure 3B). In addition, the modified 
T cells exhibited a reduced apoptosis after stimulation, 
indicated by a lower (p=0.1414) frequency of Annexin 
V+PI- cells (figure 3C). To further, evaluate effector func-
tions of the near- senescent T cells, cytokine secretion, 
degranulation and cytotoxic capacity were examined. 
Cytokine profiles were determined under steady- state 
conditions, and after activation with TA. Secretion levels 
of cytokines, with potent effector or stimulatory effect 
were elevated in Δ133p53α-overexpressing T cells (up to 
fourfold) compared with control T cells, particularly after 
antigen activation (figure 3D). Raw values are depicted 
in online supplemental figure S2. We further evaluated 
the capacity of modified T cells to mobilize lytic granules, 
analyzing the expression of the (LAMP1/CD107a). The 
data show a strong degranulation response (indicated by 
an increased expression of CD107a) of Δ133p53α-modi-
fied T cells and control T cells after TA encounter (=Ag) 
as compared with ‘residual’ response under steady- state 
(=resting) condition (figure 3E, left plot). Importantly, 
the percent of CD107a+ T cells is significantly higher in 
Δ133p53α-modified T cells (figure 3E, right plot). To vali-
date these observations, we assessed the cytolytic activity 
of Δ133p53α-engineered T cells against target tumor 
cells. Interestingly, the killing capacity was similar in both 
groups in a short- term (4–6 hours) lytic assay (figure 3F), 
yet, on repetitive coculture with tumor target cells over 
24 hours, Δ133p53α-T cells showed a remarkable stronger 
elimination of tumor cells compared with control cells 
(25% vs 40% of viable tumor colonies, figure 3G). In 
sharp contrast to Δ133p53α, p53β expression in T cells 
was associated with induction of premature senescence, 
as documented by shorter lifespan, lower CD28 and 
higher CD57 expression, higher apoptosis levels and 
low cytolytic activity (online supplemental figure S3). 
However, as opposed to Δ133p53α data, the expression of 
the immune inhibitory molecule TIGIT (and to a lesser 
extent PD-1) showed a trend toward higher levels.
TIGIT expression is antigen-dependent and affects TCR-
mediated T cell cytolytic activity
TIGIT is a central marker of T cell dysfunction and 
has been shown to be upregulated on human tumor- 
infiltrating CD8+ T cells (also regulatory T cells and 
NK cells) in a variety of cancers. Furthermore, TIGIT 
signaling can also alter T cell metabolism, as reported in 
patients with cancer.38 We then addressed the relevance 
of the reduced TIGIT expression in Δ133p53α-modified 
T cells in a functional in vitro assay. As a target tumor 
model, we used the osteosarcoma cell line Saos2/143 
that naturally express the ligands for TIGIT (CD155/
PVR) but also other inhibitory receptors, such as PD- L1 
(figure 4A). scTCR- transduced T cells were separated 
into two fractions, CD3+TIGIThigh and CD3+TIGITlow 
populations (figure 4B), and compared for their cytolytic 
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activities. As expected, TIGIThigh T cells showed a reduced 
cytolytic capacity as compared with TIGITlow T cells 
(figure 4C), which could be restored on TIGIT blockade 
(figure 4D, online supplemental figure S4A). TIGIT/
CD155 engagement can inhibit T cell function directly 
by affecting TCR signaling39; however, the mechanism 
by which TIGIT upregulation is triggered remained 
unclear. Here, we show that after encountering target 
tumor cells, the percent of TIGIT- expressing T cells 
increases to similar levels in control and Δ133p53α-trans-
duced cells, however, the expression level of TIGIT per 
cell (as determined by MFI values) remained reduced in 
Figure 2 Δ133p53α dictates metabolic reprogramming in T cells. (A) Oxygen consumption rate (OCR, left figure) and 
extracellular acidification rate (ECAR, right figure) of Δ133p53α-transduced and control cells before (Baseline) and after 
(Stressed) addition of oligomycin and FCCP measured with a XFp Extracellular Flux Analyzer. Representative of n=4 biological 
replicates, shown as mean±SEM. (B). Dot plots depicting OCR and ECAR measures for paired samples of Δ133p53α-modified 
or control T cells from four healthy donors. (C) Energy Phenotype Profile of indicated cells demonstrating the relative utilization 
of glycolysis and mitochondrial respiration. (D) Box plots showing the expression level (as mean fluorescence intensity, MFI) of 
glucose transporter 1 (GLUT1) in control and Δ133p53α-transduced cells (n≥5). (E) Protein expression of HIF- 1a in engineered 
CD8+ T cells from three healthy donors. Immunoblot (left) and dot plots (right) showing the fold change expression in Δ133p53α-
modified as compared with control T cells. Analysis of the metabolic activity, including the expression of GLUT1 and HIF- 1a 
were carried out early stage (1–3 weeks) after transduction. Error bars indicate SE of mean (SEM). *P<0.05, **p<0.01. ns, not 
significant.
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Δ133p53α-T cells as compared with control cells (700 vs 
950) (figure 4E). TIGIT upregulation is cell- cell contact 
mediated and antigen- dependent process, as coculture 
with Ag+ Saos2/143 target, but not Ag− Saos2 cells, triggers 
an increase in TIGIT expression (online supplemental 
figure S4B). This mechanism was confirmed using tumor 
Figure 3 Δ133p53α invigorates T cell proliferation, cytokine response and improves long- term killing potential of antigen TCR- 
engineered T cells. (A) Cumulative PDL of control and Δ133p53α-transduced T cells over time from a representative donor. (B) 
CFSE proliferation assay of control and Δ133p53α-overexpressing T cells after several weeks of in vitro culture. Y- axis indicates 
the reduction of intracellular CFSE on Day 4 (left plot) and Day 6 (right plot) after antigen- specific stimulation (Day 0) and was 
normalized to mode. (C) Representative flow plots of the apoptosis marker Annexin V and Propidium Iodide (PI) for control and 
Δ133p53α-transduced T cells. Summary results are depicted as paired dot plots for each individual biological replicate (n=4). 
(D) Fold change of secreted cytokines from Δ133p53α-overexpressing to control cells under resting and activated conditions 
measured by Multiplex Immunoassay at late stage in vitro culture. For activation, T cells were cultured over 24 hours with target 
tumor cells Saos2/143 (E:T=1:1) (n=2 biological replicates). (E) Degranulation Assay of control and Δ133p53α-overexpressing 
T cells again under steady- state (=resting) and activated conditions (Ag=antigen- specific stimulation) at the same time point. 
Stimulation with PMA/Ionomycin was included as positive control. Degranulation is indicated by cell surface expression of 
LAMP1/CD107a, assessed by flow cytometry. Dot chart showing the percentage of CD107a+CD8+ T cells for paired samples 
of Δ133p53α-modified or control T cells from four healthy donors. (F) 51Cr- release Assay and (G) Tumor Colony- Forming Assay 
were used to evaluate short- term and long- term antitumor responses of Δ133p53α-modified compared with control T cells. 
For 51Cr- release assay- specific lysis of target (Saos2/143) and control (Saos2p53null) tumor cells is illustrated at the indicated 
effector to target ratio (CD8+Vβ3+:T). Tumor colony- forming assays were performed over 24 hours per round with an effector to 
target ratio (CD8+Vβ3+:T) of 1:1. Remaining tumor colonies were labeled with crystal violet dye. Quantification was performed by 
measuring the optical density (OD) of the residual dye, and values expressed as per cent of tumor viability. One representative 
experiment out of four biological replicates is shown. **P<0.01. CFSE, carboxyfluorescein succinimidyl ester; E:T, effector- to- 
target; IFNγ, interferon-γ; IL, interleukin; GM- CSF, Granulocyte- macrophage colony- stimulating factor; MFI, mean fluorescence 
intensity; TNFα, tumor necrosis factor-α.
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cell- free supernatant experiments (online supplemental 
figure S4B) and p53- pulsed Saos2 cells (online supple-
mental figure S4C). In an attempt to understand the 
mechanism by which Δ133p53α overexpression correlates 
with lower TIGIT expression, we examined this pathway 
at the transcriptional level. Comparative analysis of TIGIT 
mRNA revealed lower transcripts in Δ133p53α-T cells 
in comparison with control cells (online supplemental 
figure S5A), suggesting a transcriptional regulation. To 
validate these data in a ‘gene- unmodified’ experimental 
model, we stabilized Δ133p53α expression in control T 
cells by preventing its degradation by autophagy using the 
ATPase inhibitor bafilomycin A120. We demonstrated that 
the level of TIGIT transcripts as well as TIGIT expression 
was severely reduced in T cells after treatment with bafilo-
mycin A1 (online supplemental figure S5A,B). Addition-
ally, we assessed the wide changes in histone modifications 
that might results from the overexpression of Δ133p53α 
isoform and affecting transcription at promoter sites for 
both H3K4me3 (active marks) and H3K9me3 (repressive 
marks). By testing three different biological T- cell donors, 
Figure 4 TIGIT induction is antigen- dependent and affects TCR- mediated T cell cytolytic activity. (A) Expression levels of 
PD- L1 and CD155 in the target tumor cell line Saos2/143 determined by flow cytometry. (B) Flow Cytometry Data showing 
TIGIT expression of CD8+ T cells after MACS- separation into TIGITlow and TIGIThigh population. (C) Quantified killing capacity of 
TIGITlow and TIGIThigh T cells was determined in a tumor colony- forming assay, and is expressed as the percentage of remaining 
viable tumor cells after coculture with effector T cells. (D) Quantified killing capacity of TIGITlow and TIGIThigh T cells on TIGIT 
blockade as determined in a tumor colony- forming assay. (E) Upregulation of TIGIT on CD8+ T cells before and after antigen 
recognition via coculture with Saos2/143. Percentage (left) and MFI (right) was assessed by flow cytometry. Results from one 
representative experiment out of three biological replicates are shown. MFI, mean fluorescence intensity; PD- L1, programmed 
cell death ligand 1.
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we observed a slight increase in H3K4me3 without notice-
able change in H3K9me3 (online supplemental figure 
S5C), suggesting a minor focal increase in promoter acti-
vation and gene expression in Δ133p53α-overexpressing 
T cells.
Expression of Δ133p53α in murine T cells is associated with 
reduced TIGIT levels and improved T-cell effector function
To further confirm and validate our findings, we tested 
whether the major effects of Δ133p53α demonstrated in 
human CD8+ T cells could be observed in murine T cells. 
Therefore, we cotransduced T lymphocytes from CyA2Kb 
mice with a scTCR31 and the human Δ133p53α isoform 
or a mock control. As in human T cells, Δ133p53α-trans-
duced CyA2Kb/TCR+ mouse T cells exhibited reduced 
levels of TIGIT compared with control cells (figure 5A). 
Similar results were obtained in Δ133p53α-modified T 
cells from OT- I mice (figure 5B). Similar to human T cells, 
Δ133p53α did not affect PD-1 expression levels in murine 
T cells (figure 5A,B). In addition, these models demon-
strated that Δ133p53α-modified CyA2Kb (figure 5C) or 
OT- I (figure 5D) murine T cells were able to eradicate 
target cells expressing high levels of CD155/PVR (online 
supplemental figure S6) more efficiently than control 
cells, consistent with the results of Δ133p53α in human 
T cells.
Adoptive transfer of TCR/Δ133p53α-equipped T cells results 
in superior antitumor response in vivo
Next, we assessed the antitumor efficacy of Δ133p53α 
antigen- specific TCR- modified T cells in a xenograft 
tumor model. Immunodeficient NSG mice were injected 
with Saos2/143 tumor cells, and infused with genetically 
modified- T cells (figure 6A). Δ133p53α-transduced T cells 
exhibited an improved antitumor response as reflected by 
a significantly prolonged survival of tumor bearing mice 
(figure 6B). A no transfer (PBS) experiment, to exclude 
any unspecific effect of mock- control T cells on tumor 
growth showed similar survival outcome as the control 
group (online supplemental figure S7A). Analysis of the 
starting T cell population showed comparable phenotype 
(CD4/CD8 ratio, TCRVβ3 and CD45RA/CCR7 expres-
sion levels) in Δ133p53α- and control- T cells at the time 
of infusion (online supplemental figure S7B–D). Of note, 
superior tumor control in Δ133p53α-treated mice was 
occasionally accompanied with signs of graft- versus- host 
Figure 5 Expression of Δ133p53α in murine T cells is associated with reduced TIGIT levels and improved T- cell effector 
function. (A) Representative, flow cytometric data of TIGIT and PD-1 expression of mouse T cells obtained from CyA2Kb 
mice, transduced with scTCR and of T cells obtained from OT- I mice (B). Both were transduced with human Δ133p53α or 
empty vector. Quantitative data from a representative tumor colony- forming assay using CyA2Kb TCR mouse T cells and 
A2KbMEFmutp53 (C). For OT- I cells, MC38OVA and B16OVA served as target cells (D). The optical density (O.D.) indicates the 
amount of remaining viable tumor colonies after incubation with effector T cells. PD-1, programmed cell death 1; TCR, T cell- 
receptor.
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disease (GvHD), which was characterized by loss of fur, 
reduced activity and weight loss. The development of 
GvHD was unlikely due to TCR mispairing- associated 
toxicity as we have used in this study an optimized scTCR 
with proven safety profile in vivo.31 This prompted us to 
further correlate the onset of GvHD in these animals with 
the kinetics of the Δ133p53α-T cell response. Analyses of 
spleens revealed a massive infiltration of human CD4+ and 
Figure 6 Adoptive transfer of TCR/Δ133p53α-equipped T cells results in superior antitumor response but is associated with 
cytokine release syndrome. (A) Schematic representation of the experimental model. NOD- scid IL2rgnull (NSG) were injected 
subcutaneously with Saos2/143 on day 0. T cells and IL-2 were injected intravenous on day 7 as described in the Methods. 
(B) Survival curves for mice treated with mock- control- (Ctrl), TCR- modified or TCR/Δ133p53α-modified T cells (pooled data of 
three individual experiments), n=32 mice. Significance between the animal groups was determined by log- rank test (p=0.0199). 
(C) Frequency of CD8+ and CD4+ T cells in the peripheral blood at days 7, 22 and 34 after adoptive transfer. *P<0.05, ns (not 
significant). (D) Representative data from Multiplex- Immunoassays using serum from NSG mice injected with TCR+ or TCR+/
Δ133p53α+ T cells. Serum was collected after 6 weeks, before the mice were sacrificed. ACT, adoptive cellular therapy; IFNγ, 
interferon-γ; IL-6, interleukin 6; GM- CSF, Granulocyte- macrophage colony- stimulating factor; TCR, T cell- receptor; TNF, tumor 
necrosis factor.
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CD8+ T cells in TCR/Δ133p53α mice as opposed to TCR 
control group (figure 6C, online supplemental figure 
S7E). Concordantly, Δ133p53α-T cells demonstrated a 
longer engraftment in vivo as documented by a higher 
frequency of CD8+ and CD4+ T cells in the peripheral 
blood at days 34 after adoptive transfer (figure 6D). The 
frequency of antigen- specific TCR(Vβ3)- infiltrating T 
cells was also higher, yet not significant in the spleen and 
tumor- tissue of TCR/Δ133p53α animals (online supple-
mental figure S7E). As anticipated, while the starting T 
cell population infused in mice was mainly composed of 
naïve and effector T cells, persistent T cells in vivo exhib-
ited rather an effector memory phenotype. Comparative 
analysis of sera collected from both animal groups shortly 
before sacrifice, revealed markedly increased levels of 
pro- inflammatory and immunomodulatory cytokines 
and chemokines in mice treated with Δ133p53α-T cells 
(figure 6E). These data are concordant with a previous 
study showing that Δ133p53α triggers proinflammatory 
cytokine response, including interleukin 6 (IL-6), IL-1β 
and IL-8 (via inhibition of p53 and induction of NF-κB) in 
a Helicobacter pylori infection model or cancer model.40 41
Further analysis of the TCR repertoire in spleen- 
infiltrating Δ133p53α-T cells revealed a polyclonal TCRβ 
signature (online supplemental figure S7G), indicating a 
diversity of responsive T cells in vivo.
Reverting T cell senescence of MM patients by Δ133p53α 
gene transfer
To further examine the in vivo relevance of Δ133p53α in 
the regulation of T cell senescence, peripheral blood T 
cells from newly diagnosed MM patients were phenotyped. 
MM patients had a reduced number of ‘naïve’ CD8+C-
D28+CD57- and an increased frequency of senescent- 
like CD8+CD28-CD57+ single positive (SP) T cell subsets 
(figure 7A), suggesting a senescent state of CD8+ T cells 
Figure 7 Reverting senescence in multiple myeloma (MM) patient T cells by Δ133p53α gene transfer. (A) Reduced frequency 
of CD8+CD28+CD57- (left, p=0.0014) and increased frequency of CD8+CD28-CD57+ (right, p=0.0461) T cells from MM patients 
(n=10) compared with healthy donor T cells (HC, n=15). (B) T cells from MM patients (n=27) revealed high levels of TIGIT and 
PD-1 expression compared with healthy donor T cells (HC, n=7–15) (p<0.0001). (C) Western Blot showing protein expression 
of Δ133p53α in T cells from MM patients and healthy controls (HC). Δ133p53α-transduced T cells and Saos2p53null (lane 6–7) 
served as positive and negative controls. Total protein loaded per lane was 32–60 µg for HC and MM samples. (D) Short- term 
and (E) Long- term Killing Assays comparing T cells from two MM patients with low TIGIT expression (P37, CD8+TIGIT+: 21%) 
and high TIGIT expression (P41, CD8+TIGIT+: 77%). (F) Overexpression of Δ133p53α in T cells from a MM patient (MM305) 
resulted in reduced frequency of TIGIT- expressing T cells (flow plota) and lower expression levels (MFI plot). (G) Phenotype of 
CD8+T cells from two myeloma patients (MM305, MM306) prior (pie chart, left) and after (flow plots, right) retroviral transduction 
with ctrl or Δ133p53α. Expression intensity of CD45RA and CD62L expression in CD8+ engineered T cells are shown as MFI 
plots. (H) Dot chart showing the percentage of CD27+CD8+ T cells for paired samples of Δ133p53α-modified or control T cells 
from three MM patients. (I) Short- term Killing Assays of T cells from the same patient (MM305) transduced with Δ133p53α or 
control vector exhibited an improved cytolytic response by Δ133p53α-overexpression at different effector (CD8+Vβ3+) to target 
(T) ratios. Error bars indicate SE of mean (SEM). *P<0.05, ***p<0.001, by two- tailed Student’s t- test. MFI, mean fluorescence 
intensity; PD-1, programmed cell death 1; TCR, T cell- receptor.
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in MM patients. Interestingly, analysis of the fraction of 
total CD28+ and CD57+ in CD8+ T cells showed similar 
expression profiles (online supplemental figure S8). 
Furthermore, we observed a markedly increased expres-
sion of the T cell- associated senescent markers TIGIT and 
PD-1 in MM patients (figure 7B). We then anticipated 
a reduced expression of the Δ133p53α isoform in MM 
as compared with healthy individuals. Protein expres-
sion data confirmed high levels of Δ133p53α-isoform 
in healthy individuals, while marginal or no expression 
was detected in MM patient T cells (figure 7C). Next, 
we evaluated the senescence status of MM CD8+ T cells 
in functional assays. T cells from two patients (P37 and 
P41) with distinct TIGIT, CD28SP and CD57SP expres-
sion profiles were selected. P41 and P37, characterized as 
TIGIThighCD57SPhighCD28SPlow and TIGITlowCD57SPlow-
CD28SPmild, were genetically equipped with a scTCR and 
tested for their antigen specific response. In both, short- 
term (figure 7D) and long- term (figure 7E) killing assays, 
P41-, but not P37- modified T cells, exhibited a severely 
impaired cytotoxic capacity against target Saos2/143 
tumor cells. To explore the possibility to reprogram 
senescent T cells of MM patients into more ‘juvenile’ and 
effective T cells, we performed Δ133p53α gene transfer 
experiments in MM T cells. In line with our data from 
healthy individuals, Δ133p53α overexpression was associ-
ated with more than a twofold reduction in TIGIT expres-
sion (figure 7F). While the starting CD8+T cell population 
from two myeloma patients (MM305, MM306) prior trans-
duction was mainly composed of naïve, effector memory 
(CD45RA- CCR7-) and effector (CD45RA+CCR7-) pheno-
type, the phenotype following transduction with TCR 
control vector showed a dominant effector memory and 
a low percentage (6% and 15%) of CD45RA+CD62L+ 
(naive). The frequency of naïve population as well as 
the expression intensity of both CD45RA and CD62L 
markers increased (twofold and fivefold) after overex-
pression of the Δ133p53α isoform (figure 7G). In line, 
Δ133p53α-modified MM T cells exhibit a higher expres-
sion of the costimulatory molecule CD27 (figure 7H). 
Importantly, Δ133p53α gene transfer in MM patient T 
cells promoted superior specific cytolytic activity against 
Saos2/143 tumor cells (figure 7I).
DISCUSSION
Senescence- induced T cell dysfunction in the TME 
impedes the clinical efficacy of cancer immunotherapy.9 14 
An age- dependent accumulation of senescent T cells in 
healthy individuals which was associated with changes in 
expression of T cell surface markers and p53 isoforms 
has been described. In this study, p53β and Δ133p53α 
were identified as potential opposite markers for cellular 
senescence by providing evidence that overexpression of 
Δ133p53α could restore the proliferation capacity of late 
differentiated or senescent T cells in vitro.20 However, it 
remained unclear whether and how these isoforms can 
modulate TA- specific T cell functions, in particular in 
more complex in vivo tumor suppressive environment.
Here, we demonstrated that gene expression of 
Δ133p53α is associated with a metabolic switch and 
profound functional changes in TA- specific cytotoxic 
CD8+ T cells in vitro and in mouse tumor model. Pheno-
typing of T cells revealed a shift toward a less differen-
tiated state characterized by an upregulation of CD28, 
CD27 and CD62L and a downregulation of key inhib-
itory receptors, CD160 and TIGIT. Accordingly, we 
observed a prolonged long- term proliferative potential 
and improved effector functions as demonstrated by 
enhanced tumor- specific cytolytic activity and a superior 
cytokine response in vitro. In contrast, p53β expression 
in T cells drives premature senescence phenotype, char-
acterized by a lower CD28 and higher CD57 expression, 
higher apoptosis levels along with a shorter life- span.
T cells can modulate their cellular metabolism according 
to their functional needs.34 However, this metabolic switch 
can be altered by the TME which can lead to T cell dysfunc-
tion.42 Along with the induction of a less differentiated 
phenotype and enhanced effector functions, our results 
showed that Δ133p53α is associated with a metabolic 
reprogramming in tumor- reactive engineered CD8+ T cells 
characterized by a quiescent metabolic state with lower 
glycolytic activity and expression of GLUT1. This is in line 
with a recent study reporting that CD8+ T cells with a low 
mitochondrial membrane potential (ΔΨm) are enriched 
in CD62L+ central memory T cells, accompanied with a 
reduced glycolytic activity and mitochondrial respiration 
leading to enhanced proliferative capacity and increased 
antitumor activity in vivo.43 The reduced metabolic activity 
early after transduction may be adapted to low metabolic 
demands, which may be increased for rapid expansion 
after activation.
T cell metabolism can be altered in patients with cancer 
through TIGIT/CD155 signaling.44 Moreover, TIGIT/
CD155 interaction is also involved in the suppression of T cell 
activation.5 45 TIGIT was found to be upregulated on human 
tumor- infiltrating lymphocytes44 46 and its blockade improved 
CD8+ T cell effector functions.5 47 Moreover, CD8+ T cells 
from aged healthy donors, exhibited a high TIGIT expres-
sion, accompanied by impaired effector functions.48 Here, we 
demonstrated for the first time the effect of Δ133p53α on 
TIGIT expression in antigen- specific T cells at the mRNA and 
protein levels. Additionally, T cells with high TIGIT expres-
sion had a compromised cytolytic response against CD155- 
expressing target cells. Consistently, T cell dysfunction in 
patients with MM14 has been recently attributed, among other 
factors, to high TIGIT expression.47 49 Accordingly, TIGIT 
blockade could restore anti- myeloma T- cell function.47 In the 
present study, we could confirm the senescent phenotype and 
high expression of TIGIT in T cells from newly diagnosed 
MM patients and further revealed a reduced expression of 
Δ133p53α. In line with our results from healthy donors T 
cells, TIGIThigh- expressing MM T cells showed impaired anti-
tumor responses which could be restored on Δ133p53α gene 
transfer. Improved T cell function of Δ133p53α-modified 
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MM T cells was associated with a less differentiated pheno-
type characterized by de novo expressions of CD45RA, CD27 
and CD62L. Thus, these results further demonstrate the 
capacity of Δ133p53α to reinvigorate effector functions of 
cancer patient- derived senescent T cells. On a more transla-
tional level, a lower expression of the senescence- associated 
and negative immune receptor TIGIT in antigen- TCR CD8+ 
T cells overexpressing Δ133p53α is novel (as it has not yet 
been reported) and has potential clinical relevance. TIGIT is 
emerging as the third (after CTLA-4 and PD-1) clinical target 
in immuno- oncology. Currently, more than 20 clinical trials 
testing anti- TIGIT agents (as single treatment or in combina-
tion with PD- (L)1 blockade) are launched by lead biophar-
maceutical companies (such as Roche, BMS and Merck), 
including five phase 3 studies in solid cancers (glioblastoma, 
melanoma, lung, breast cancer, …) and hematological malig-
nancies (MM).
Using a preclinical tumor model, we observed enhanced 
antitumor responses in Δ133p53α-T cells leading to supe-
rior overall survival of treated mice. This improved anti-
tumor immunity was occasionally accompanied by a severe 
inflammatory response, confirmed by elevated levels of 
secreted cytokines in the serum and massive infiltration 
of T cells in the spleen. These findings suggest a cytokine- 
associated toxicity resulting from rare hyperactivated T 
cells induced by Δ133p53α, consistent with the profound 
proinflammatory phenotype reported in transgenic mice 
expressing a Δ133p53α-like isoform.50 These data calls for a 
safety approach to limit excessive immune response associ-
ated with sustained expression of Δ133p53α in engineered 
T cells. These potentially severe side effects caused by strong 
immune activation may be resolved with monoclonal anti-
bodies against certain cytokines (like Tocilizumab), or by 
using a safety switch approach like an inducible caspase 9 
suicide system.
In conclusion, our data demonstrated that Δ133p53α 
isoform acts as a potent enhancer of robustness and resil-
ience in human cytotoxic T cells, which may represent a novel 
approach to improve T- cell- based cancer immunotherapies.
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Supplemental data 1 
 2 
 3 
Figure S1. 133p53 modulates the function of the full-length p53. (A) Immunoblot analysis 4 
of the expression of p21Waf1/Cip1 and MDM2 as p53 target genes in human CD8+ T cells 5 
transduced with an empty control (ctrl) vector or retroviral vector encoding for 133p53 6 
isoform. (B) Summary data from 5-6 heathy are shown. Data were normalized to GAPDH and 7 
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Figure S2. 133p53 invigorates cytokine response of antigen TCR-engineered T cells.  3 
Cytokine profiles of 133p53-overexpressing and control T cells under steady-state 4 
(=resting) and after tumor antigen encounter (=activated) as measured by Multiplex 5 
Immunoassay at late stage in vitro culture. For activation, T cells were cultured over 24 hours 6 
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cytometry using anti-TCRV3 mAb. (C) Flow cytometry plots depicting cell surface expression 1 
of CD28 and CD57 single positive (SP) for paired samples of p53-modified or control CD8+ T 2 
cells from different donors (n≥6). (D) Difference in TIGIT and PD-1 expression between control 3 
and p53-transduced cells shown for each individual donor (n≥6). (E) Cumulative PDL of 4 
control and p53-transduced CD8+ T cells over time from two representative donors. (F) 5 
Representative flow plots of Annexin V and Propidium Iodide (PI) staining for control and p53-6 
transduced T cells, and the corresponding graphs depicting individual donors (n=4). (G) Long-7 
term cytolytic activity of p53-modified compared to control T cells as determined by Tumor 8 
Colony-Forming Assay (see Methods section). One representative experiment out of four 9 
biological replicates is shown. *P < 0.05, **P < 0.01, ns (not significant), by two-tailed Student’s 10 
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Table S1. Antibodies for flow cytometry 1 
antibodies clone source 
anti-human CD3, APC UCHT1 BD Biosciences 
anti-human CD3, APC-R700 UCHT1 BD Biosciences 
anti-human CD4, FITC RPA-T4 BD Biosciences 
anti-human CD45, APC-H7 2D1 BD Biosciences 
anti-human CD8, APC RPA-T8 BD Biosciences 
anti-human CD8, FITC HIT8a BD Biosciences 
anti-human CD27, PE M-T271 BD Biosciences 
anti-human CD27, APC REA499 Miltenyi Biotec 
anti-human CD28, FITC CD28.2 BD Biosciences 
anti-human CD28, PE CD28.2 BD Biosciences 
anti-human CD57, APC NK-1 BD Biosciences 
anti-human CD57, BV421 NK-1 BD Biosciences 
anti-human CD62L, PC-5 DREG56 Immunotec 
anti-human CCR7, FITC 150503 R&D Systems 
anti-human PD-L1, APC MIH1 BD Biosciences 
anti-human PD-1, APC J43 ThermoFischer Scientific 
anti-human PD-1, FITC MIH4 BD Biosciences 
anti-human PD-1, BV421 EH1.21 BD Biosciences 
anti-human CD160, PE BY55 BD Biosciences 
anti-human TIGIT, APC REA1004 Miltenyi Biotec 
anti-human TIGIT, PE-Cy7 A15153G BioLegend 
anti-human TIGIT, PE MBSA43 Invitrogen 
anti-human CD155, APC 300907 R&D Systems 
anti-human CD155, PE SKII.4 BD Biosciences 
anti-human CD107a, PE-Cy5 H4A3 BD Biosciences 
anti-human CD45RA, PE HI100 BD Biosciences 
anti-murine TCRV3, PE KJ25 BD Biosciences 
anti-human CD155 (neutralizing)  SKII.4 BioLegend 
anti-human TIGIT (neutralizing) MBSA43 eBioscience 
anti-HLA-A2.1, PE BB7.2 BD Biosciences 
Anti-human GLUT1-Alexa Fluor® 647 202915 BD Biosciences 
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anti-murine TIGIT, BV421 1G9 BD Biosciences 
anti-murine TIGIT, PE REA536 Miltenyi Biotec 
anti-murine PD-1, APC J43 Invitrogen 
anti-murine CD155, PE 3F1 BD Biosciences 
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Table S2. Primers for qRT-PCR 1 
Target Forward Reverse 
TIGIT TGCCAGGTTCCAGATTCCA ACGATGACTGCTGTGCAGATG 
GAPDH GTTTACATGTTCCAATATGATTCCAC TCATATTTGGCAGGTTTTTCTAGAC 
 2 
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